STOCK MARKET BSE NSE

Dr Reddy's Labs Migraine Injection Enters US Market

At the time of USFDA approval, DRL had said the new product will be marketed in the US by Promius Pharma.

Published: 19th April 2016 06:24 PM  |   Last Updated: 19th April 2016 06:24 PM   |  A+A-

By ANI

NEW DELHI:: Dr Reddy's Laboratories (DRL) in an announcement stated that their acute migraine treatment injection ZembraceSymTouch is now commercially available in the US market.

In a BSE filling, the company said that ‘Promius Pharma LLC’, a subsidiary of DRL announced that ZembraceSym Touch injection is now commercially available in the US.

They received an approval from the US Food and Drug Administration (USFDA) for ZembraceSymTouch injection in January this year. ZembraceSymTouch is available as a prefilled, ready to use, single dose disposable injector.

At the time of USFDA approval, DRL had said the new product will be marketed in the US by Promius Pharma.

"ZembraceSymTouch is the first branded product in the company's neurology portfolio," DRL Executive Vice President Propriety Products Group, Raghav Chari said. (ANI)

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp